AI-assisted, human-published
12/10/2024 /Funding Events
Qnovia, Inc. Secures $16 Million in Series B Funding for RespiRx™ Nicotine Inhaler Development
Pharmaceutical company Qnovia raises $16 million in Series B funding to propel RespiRx™ Nicotine Inhaler towards MAA submission and commercialization in the UK.
AI-assisted, human-published
Latest headlines
-
-
-
Stay connected!
If you have a serious, bonafide inquiry into the VentureCapital.com or PrivateEquity.com domain names, please contact us here
©2023 VentureCapital.com